类风湿关节炎联合治疗方案解析
RA是一种以慢性侵蚀性关节损伤为主要表现的系统性自身免疫病,如果未及时治疗,患者可出现关节软骨破坏或骨质破坏,最终导致关节畸形,致残率很高。不仅如此,RA还可伴有关节外的系统性损害,严重危害患者的健康和生活质量。
01、联合用药的优势
02、联合用药的时机
03、不同的联合治疗方案
04、联合治疗存在的问题
结语
参考文献:
[1] 中华医学会风湿病学分会.2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志,2018,4(54):242-251.
[2] 黄烽.《类风湿关节炎联合治疗必要性探讨》[J].中华风湿病学杂志,2004,8(5):259-261.
[3]刘念,张秀灵,尚静静等. 甲氨蝶呤联合传统DMARDs与联合生物制剂治疗RA的疗效比较[J]. 南昌大学学报(医学版),2017,57(6):32-36.
[4] Jorgensen C,Sun R,Rossi JF,et a1.Expression of a muhidrug resistance gene in human rheumatoid synovium.Rh eumatol Int,1995,15:83-86.
[5] 陈楠,王振刚.《以甲氨蝶呤为核心的类风湿关节炎的联合药物治疗》[J].《中国医刊》2013,48(7):5-7.
[6] 陈颖娟,高洁生,吴轰等.不同DMARDs联合用药治疗类风湿关节炎疗效与安全性[J]. 中国现代医学杂志,2005,15(4):576-581.
[7] 王振杰.甲氨蝶呤与艾拉莫德联合治疗难治性类风湿关节炎的疗效及安全性分析[J].中国现代药物应用,2016,10(23):105-106.
[8] Van Nies JA,Krabben A,Schoones JW,et a1.What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review[J].Ann Rheum Dis,2014,73(5):861-870.
[9]Raza K,Saber TP,Kvien TK,et a1.Timing the therapeutic window of opportunity in early rheumatoid arthritis:proposal for definitions of disease duration in clinical trials[J].Ann
Rheum Dis,2012,71(12):1921-1923.
[10]O Dell JR,Haire CE,Erikson N,et a1.Treatment of rheumatoid arthritis with methotrexate alone,sulfasalazine an d hydroxychloroquine,or a combination of all three medications.New Engl J Med,1996,334:1287-1291.
[11] 李振彬.类风湿关节炎的现代治疗策略与方法[J].《临床荟萃》,2016,31(5):486-489.
[12]Kekow J,Moots RJ,Emery P,et a1.Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission:the COMET trial[J].Ann Rheum Dis,2010,69(1):222-225.
[13] Li J, Mao H, Liang Y, et al. Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis[J]. Clin Dev Immunol, 2013, 2013(7):310628. DOI: 10.1155/2013/310628.
[14] Hara M, Ishiguro N, Katayama K, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate
response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial[J]. Mod Rheumatol, 2014, 24(3):410-418. DOI: 10.3109/14397595.2013.
843756.
[15]Lau CS, Chia F, Harrison A, et al. APLAR rheumatoid arthritis treatment recommendations[J]. Int J Rheum Dis,2015, 18(7):685-713. DOI: 10.1111/1756-185X.12754.
[16]Lau CS, Chia F,Dans L, et al.2018 update of the APLAR recommendations for treatment of rheumatoid arthritis[J]. Int J Rheum Dis, 2019 Mar;22(3):357-375. DOI: 10.1111/1756-185X.13513.
来源:医库
您可能关注的内容: